Our previous study also showed that high stathmin expression predicted an unfavorable prognosis in patients with ovarian cancer who received paclitaxel and platinum chemotherapy, supporting the possibility that stathmin may interfere with paclitaxel treatment, leading to a poor prognosis (19). Here, STMN1 is linked to ovarian carcinoma.